- authorisedTherapeutic exploratory (Phase II)
SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL
This study looks at a medicine called dapagliflozin (Forxiga) for people on dialysis with kidney problems, both with and without diabetes. We want to see if it helps reduce a common heart issue called Left Ventricular Hypertrophy, which is when the heart muscle thickens.
Austria - ongoing, recruitingTherapeutic use (Phase IV)
Evaluation of the effect of tacrolimus on carbohydrate metabolism in pre-renal transplantation dialysis patients
France